Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined.  Read the press release >